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Decisions regarding the legal status of cannabis have long been
framed (for the public at least) with reference to the perceived
health risks and harms associated with use. Yet, drug policy and
legislation relating to the use of cannabis are rarely based on the
scientific evidence of the known risks and harms. There are many
reasons for this discrepancy, with the politicization of cannabis
use, where ideology and moralizing are given precedence over the
science, being one. Thus, we begin this research topic with Aggar-
wal (1) discussion of how such politicization has contributed to
the current smokescreen that is obscuring our understanding of
cannabis, including the impact it has on the ability of researchers
to collect and disseminate accurate information about the effects
of cannabis use.
The capacity of policy makers and legislators to develop
evidence-based cannabis policies and laws is also contingent on
researchers explaining the existing evidence, disseminating new
research findings, and collaborating with relevant people, agen-
cies, and government departments to improve the premises on
which they base their policies and legislation. Roffman (2), who
took this path through his involvement in the development of the
legislation to legalize cannabis use in Washington State, provides
an insider’s view of the processes and deliberations. While we will
have to wait for the evaluation of this carefully designed model for
regulating cannabis use, the following two articles provide some
insight into patterns of cannabis use in contexts were consumption
is relatively normalized. There are many parallels evident in the
findings of Mostaghim and Hathaway (3) qualitative exploration
of cannabis use among Canadian university students and Liebregts
et al. (4) prospective investigation of cannabis use by young adults
transitioning from university to work in The Netherlands. Of par-
ticular note are the ways in which the participants’ self-identity,
including priorities, roles, and responsibilities, act as constraints
to their use, and the clear demarcations drawn between leisure and
work.
A major consideration, discussed by Roffman (2), was the risk
that legalization of cannabis might spark an increase in usage,
which could, in turn, result in higher incidence and prevalence of
cannabis-related harms, particularly if there was an increase in use
by adolescents. The evidence underpinning concerns of adverse
impacts resulting from early onset cannabis use is reviewed by
Chadwick et al. (5), who report that adolescent users with genetic
vulnerabilities are at increased risk of experiencing motivational,
affective, and psychotic disorders, including schizophrenia. The
association between cannabis and psychosis/schizophrenia is com-
prehensively reviewed by Radhakrishnan et al. (6), who conclude
that, while, cannabis may be a component cause in the develop-
ment of psychosis, this association is moderated by family history
of psychoses, genetic factors, childhood trauma/abuse, and age at
onset of use. The importance of differentiating between psychotic
disorders and psychomimetic effects is also highlighted as being
an essential step in increasing our understanding of the cannabis-
psychosis association. Similarly, the two pathways from cannabis
use to psychosis proposed by Burns (7) illustrate the importance
of differentiating between types of cannabis-psychosis trajectories,
showing how the clinical presentation profiles and treatment out-
comes differ for early onset, long-term cannabis use in comparison
to later onset, short-term but intense use.
Early onset/adolescent cannabis use is investigated further in
the next three articles. First, Serafini et al. (8) explore the possi-
ble role of hopelessness as a mediator in the relationship between
early cannabis use and suicidal behaviors, while Little et al. (9)
investigate predictors of cannabis cessation within a sample of
high-school students. The next article, by Fallu et al. (10), reports
the findings of a latent class analysis of adolescent cannabis users,
revealing four different use trajectories. The early onset, heavy
cannabis and polydrug use group in this study were found to
experience the highest level of use-related problems, followed
by the late-heavy-polydrug group. Similarly, Connor et al. (11)
report that, in a sample of adult cannabis users referred for treat-
ment, those who engaged in polydrug use were more likely to be
cannabis dependent and experiencing higher levels of comorbid
psychopathology, than individuals who used cannabis, tobacco,
and/or alcohol. Healey et al. (12) also focused on a treatment
sample, finding that both cannabis users and their clinicians
reported difficulty in establishing a therapeutic bond. A dose–
response relationship was evident for the client perspective, such
that heavier users reported feeling less connected, which the
authors suggest may be related to effects of cannabis use such
as paranoia or anxiety. The association between cannabis use and
anxiety is explored by Temple et al. (13), who test the premise
that the contradictory findings in the literature for this associ-
ation may be due to individuals misattributing stress responses
to anxiety symptomology. The finding that stated use to self-
medicate for anxiety is more strongly associated with level of
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stress rather than anxiety symptoms provides some support for
this hypothesis.
The therapeutic potential of cannabis is one of the factors dri-
ving the push for legalization of cannabis use. Yet, as discussed by
Crippa et al. (14), with the majority of past research focus being
on cannabis as a whole or THC, we have limited knowledge of the
mechanisms of action of the many other cannabinoids, which is
impeding our understanding of their medical applications. One
of the key areas of current research into the therapeutic effects of
cannabis focuses on the ability of CBD to modulate the adverse
psychological effects of THC; this body of evidence is reviewed
here by Niesink and van Laar (15). Oliere et al. (16) similarly focus
on the therapeutic potential of cannabinoids, comprehensively
reviewing what is known about the role of the endocannabinoid
system in addiction and demonstrating the possibility of using
cannabinoids to treat stimulant dependence. The focus on indi-
vidual cannabinoids is also relevant to the issue of doping in sports,
as is discussed by Bergamaschi and Crippa (17), who point out that
focusing on THC metabolites for drug testing ignores the perfor-
mance enhancing potential of other cannabinoids, such as CBD
and CBN.
The final article in this research topic, by Burns et al. (18), urges
researchers to reflect on the different indicators of cannabis use,
demonstrating how the data we collect and inferences drawn will
differ if we focus on the prevalence of cannabis use, for example,
rather than the quantity of cannabis used or the frequency of use.
This article, along with the others collected here, encourage
cannabis researchers to reflect on the ways in which we frame our
research questions, design our studies, and explain our findings,
so as to improve the clarity of the evidence. While we may not be
able to clear the politicized smokescreen currently shrouding the
evidence, ultimately, it is our responsibility to ensure that there
is a comprehensive body of scientific knowledge available for the
development of evidence-based cannabis policies and legislation
when the fresh air does eventually blow through.
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